Cutting-edge MRD detection for every point of patient care

Leading cancer centers standardize on clonoSEQ®, using it to precisely identify minimal residual disease (MRD) at the DNA sequence level. When integrated into routine clinical practice, clonoSEQ is an essential part of advancing patient care in lymphoid malignancies.


Applying clonoSEQ to the clinical setting

Learn how clinicians at top cancer centers incorporate clonoSEQ in routine clinical practice to make treatment decisions and inform patient care.

View case studies and perspectives

Ultra-sensitive MRD detection

The FDA-cleared clonoSEQ Assay is a highly sensitive, specific, and standardized method for detecting and monitoring MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).[1,2] MRD refers to the small number of cancer cells that can remain in a patient’s body during and after treatment and may eventually cause recurrence of the disease.

clonoSEQ leverages the power of next-generation sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.[1,2]

clonoSEQ can help clinicians:

Specimen requirements, report tutorials, reimbursement support services for patients, and more

Download resources

News and updates

Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients

Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin’s Lymphoma.


December, 2020

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting


August, 2020

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia.


This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA validated laboratory developed test (LDT). IGHV testing is available as a CLIA-validated LDT and has not been cleared or approved by the FDA. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.


  • Ching T, et al. BMC Cancer. 2020;20:612.
  • Pulsipher M, et al. Blood. 2015;125(22):3501-3508.